I don’t know how much longer Brooks Automation (BRKS) will operate as is, what with the Street preferring more pure-plays these days, but for the time being this is an interesting way for investors to pursue exposure to two attractive growth markets – leading-edge semiconductor manufacturing and life sciences, with an attractive “kicker” to gene therapy in the latter.
Not surprisingly, Brooks doesn’t trade a like a value stock, and this stock is going to have more appeal to investors who care more about growth and growth stories than by-the-numbers valuation. While I do like the long-term growth potential of both businesses, I would note cyclical risk in the semiconductor business and valuation risk in life sciences given the high level of investor enthusiasm for plays in that sector.
Read more here:
Brooks Automation Offers A Two-For-One With Exposure To 2 Healthy Growth Markets
No comments:
Post a Comment